Evaluation of the relationship between KIM-1 and suPAR levels and clinical severity in COVID-19 patients: A different perspective on suPAR.


Journal

Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876

Informations de publication

Date de publication:
Sep 2021
Historique:
revised: 15 05 2021
received: 09 03 2021
accepted: 18 05 2021
pubmed: 22 5 2021
medline: 3 8 2021
entrez: 21 5 2021
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) is one of the most pressing health problems of this century, but our knowledge of the disease is still limited. In this study, we aimed to examine serum-soluble urokinase plasminogen activator receptor (suPAR) and kidney injury molecule 1 (KIM-1) levels based on the clinical course of COVID-19. Our study included 102 patients over the age of 18 who were diagnosed as having COVID-19 between September 2020 and December 2020 and a control group of 50 health workers over the age of 18 whose severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PCR results were negative. KIM-1 was measured by ELISA and suPAR by suPARnostic™ assay. Analysis of previously identified variables of prognostic significance in COVID-19 revealed high neutrophil to lymphocyte ratio, lactose dehydrogenase, prothrombin time, C-reactive protein, PaO

Identifiants

pubmed: 34019703
doi: 10.1002/jmv.27099
pmc: PMC8242801
doi:

Substances chimiques

Biomarkers 0
HAVCR1 protein, human 0
Hepatitis A Virus Cellular Receptor 1 0
PLAUR protein, human 0
Receptors, Urokinase Plasminogen Activator 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5568-5573

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

J Intern Med. 2015 Mar;277(3):362-371
pubmed: 24830873
Infez Med. 2020 Ahead of print Jun 1;28(2):174-184
pubmed: 32275259
Sci Rep. 2017 Jan 16;7:40627
pubmed: 28091558
J Mol Cell Biol. 2021 Jul 6;13(3):185-196
pubmed: 33493263
Int J Environ Res Public Health. 2019 Mar 21;16(6):
pubmed: 30901954
J Med Virol. 2021 Apr;93(4):2090-2098
pubmed: 33038012
Postgrad Med J. 2018 Sep;94(1115):517-524
pubmed: 30177549
ERJ Open Res. 2019 Mar 25;5(1):
pubmed: 30918897
J Clin Lab Anal. 2015 Sep;29(5):347-52
pubmed: 25043869
Clin Immunol. 2020 Jun;215:108427
pubmed: 32325252
Chest. 2018 Feb;153(2):361-367
pubmed: 29248620
Aging (Albany NY). 2020 Jun 5;12(11):10087-10098
pubmed: 32501810
Int J Epidemiol. 2020 Jun 1;49(3):717-726
pubmed: 32086938
Int J Chron Obstruct Pulmon Dis. 2015 Feb 13;10:357-65
pubmed: 25709430
BMC Med. 2012 Jan 05;10:2
pubmed: 22221662
Eurasian J Med. 2020 Jun;52(2):224-226
pubmed: 32612435
Lung. 2020 Oct;198(5):777-784
pubmed: 32918573
J Clin Virol. 2020 Jun;127:104361
pubmed: 32344320
J Am Soc Nephrol. 2020 Nov;31(11):2725-2735
pubmed: 32963090
Radiology. 2020 Dec;297(3):E335-E338
pubmed: 32407256
Clin Biochem. 2013 Feb;46(3):225-9
pubmed: 23159293
Drug Discov Today. 2020 Aug;25(8):1528-1534
pubmed: 32562843
Clin Biochem. 2015 Dec;48(18):1324-9
pubmed: 26162494
Eur J Clin Invest. 2016 Apr;46(4):305-11
pubmed: 26799247
J Med Virol. 2021 Sep;93(9):5568-5573
pubmed: 34019703
Acta Anaesthesiol Scand. 2021 Mar;65(3):364-372
pubmed: 33190222

Auteurs

Buğra Kerget (B)

Department of Pulmonary Diseases, Ataturk University School of Medicine, Yakutiye, Erzurum, Turkey.

Ferhan Kerget (F)

Department of Infection Diseases and Clinical Microbiology, Health Sciences University Erzurum Regional Education and Research Hospital, Yakutiye, Erzurum, Turkey.

Alperen Aksakal (A)

Department of Pulmonary Diseases, Health Sciences University Erzurum Regional Education and Research Hospital, Yakutiye, Erzurum, Turkey.

Seda Aşkın (S)

Department of Biochemistry, Ataturk University School of Medicine, Yakutiye, Erzurum, Turkey.

Elif Yılmazel Uçar (EY)

Department of Pulmonary Diseases, Ataturk University School of Medicine, Yakutiye, Erzurum, Turkey.

Leyla Sağlam (L)

Department of Pulmonary Diseases, Ataturk University School of Medicine, Yakutiye, Erzurum, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH